CRVS vs GS · $1.04B cap vs P/E 20, rev $37.56B
Corvus Pharmaceuticals Inc (CRVS) versus Goldman Sachs Group Inc (GS) — a side-by-side from cached financials, not a winner call.
Corvus Pharmaceuticals Inc (CRVS) is a biotechnology company listed on US.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
CRVS does not have a complete income-statement cache yet.
Latest reported GS revenue for 2026-06-30 was $37.56B. Net income was $12.26B. GS currently screens at market cap $324.25B and trailing P/E 20.1.
CRVS currently screens at market cap $1.04B. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Not investment advice. Open the CRVS and GS stock pages for the full models.
Not investment advice.